Tests probucol to lower repeat stroke risk in narrowed artery patients
Tests probucol versus placebo in adults with narrowed brain or neck arteries after stroke.
Plain-language title generated from the registry record
Registry title: Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis
Key facts
- Where
- Wuhu, ChinaSee the site
- Phase
- Phase 3
Where in China
- The First Affliated Hospital of Wannan Medical CollegeWuhu, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Wannan Medical College
- Trial code
- NCT06225752
- Record updated
- 30 October 2026
- Original description
This study is a multicenter, double-blind, placebo-controlled, randomized clinical trial that aims to evaluate the efficacy of probucol on the reduction of the risk of recurrent stroke in patients with symptomatic intracranial or extracranial arterial stenosis.Read full original descriptionShow less
A Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial of Probucol in Reducing the Risk of Recurrent Stroke in Patients With Symptomatic Intracranial and Extracranial Large-artery Stenosis
This study is a multicenter, double-blind, placebo-controlled, randomized clinical trial that aims to evaluate the efficacy of probucol on the reduction of the risk of recurrent stroke in patients with symptomatic intracranial or extracranial arterial stenosis.
Inclusion: 1.40 years or older than 40 years; 2.Ischemic stroke or transient ischemic attack (TIA); 3.Within 7 days from onset to randomization; 4.Main intracranial or extracranial arteries supplying the ischemic event region are narrowed by more than 50%; 5.Informed consent signed.
Exclusion: Usage of probucol within 30 days before randomization; With Q-Tc interval prolongation, or currently using drugs that may cause Q-Tc interval prolongation (male Q-Tc>450ms, female Q-Tc>470ms); Planned surgery or interventional treatment requiring cessation of the study drug during the study; Participating in another clinical trial with an investigational drug or device concurrently or during the last 30 days; Serious drug or alcohol abuse in the past 1 year；; Presumed cardiac source of embolus, such as atrial fibrillation, prosthetic cardiac valve, endocarditis or patent foramen ovale; Stroke/TIA due to arterial dissection, angioplasty, or vascular surgery; Known allergy or sensitivity or intolerance to probucol; Myocardial disease within the past 30 days, including myocardial infarction, myocarditis; Cardiac syncope or unexplained syncope; Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders, or to be an unsuitable candidate for the study for any other considered by the investigator; Impaired hepatic (ALT or AST > twice the upper limit of normal range) or kidney (creatinine exceeding 1.5 times of the upper limit of normal range or eGFR less than 50 ml/min) function at randomization; Anemia (haemoglobin <10g/dL), thrombocytopenia (platelet count <100×109/L) or leucopenia (white blood cell <3×109/L) at randomization; With ventricular tachycardia, bradycardia, tip-twist ventricular tachycardia；; Pregnant or lactating women; Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control; Severe non-cardiovascular comorbidity with a life expectancy of less than 1 years.